Navath RS, Kurtoglu YE, Wang B, Kannan S, Romero R, Kannan RM: Dendrimer-drug conjugates for tailored intracellular drug release based on glutathione levels
Este compuesto juega un papel importante en nuestro cuerpo, escoltando a los cidos grasos de cadena larga a las mitocondrias de las clulas, donde producen energa
intravenous (some studies) Protocol: Cyclic -- 5-10 mg/day for 10-20 consecutive days, repeated every 4-6 months (2-3 cycles per year) Rationale: Brief telomerase activation extends telomeres, which then provide sustained replicative capacity during drug-free intervals Requirements: Sterile reconstitution, cold chain storage, injection supplies, injection technique Regulatory status: FDA Category 2 since 2024 (banned from compounding in the US) NAD+# Route: Oral (NMN, NR supplements)
Lipolytic : stimulates the consumption of fats as a source of energy
Earlier studies showed HN019 reduced colonic transit time and improved bowel movement frequency at doses ranging from 1 to 17 billion CFU per day in adults
only one opened unit of the same product per most recent order qualifies for full refund)